Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + VCD induction before ASCT in newly diagnosed multiple myeloma
ACTRN12618001085268Phase 2Completed
- Sponsor
- Alfred Health
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, bortezomib, cyclophosphamide, dexamethasone and melphalan in multiple myeloma (MM), sponsored by Alfred Health. Primary endpoint: Complete response rate / clinical benefit response rate by serum assay. Started Nov 2018; status: completed.
02
Drugs
venetoclaxbortezomibcyclophosphamidedexamethasonemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12618001085268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001085268.